The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.
Department of Pathology, Duke University Medical Center, Durham, North Carolina.
Cancer Discov. 2020 Nov;10(11):1629-1631. doi: 10.1158/2159-8290.CD-20-1215.
Tumors mutated in IDH1 tend to have lower levels of the essential substrate NAD. In this issue of , Nagashima and colleagues exploit this metabolic sensitivity by devising a combinatorial therapy that both further reduces the pools as well as sequesters the remaining substrate in PAR chains, sensitizing the cells to temozolomide and PARG inhibition..
IDH1 突变的肿瘤往往 NAD 的必需底物水平较低。在本期的《 》中，Nagashima 及其同事利用这种代谢敏感性，设计了一种组合疗法，既能进一步减少 PAR 链中的池，又能隔离剩余的底物，使细胞对替莫唑胺和 PARG 抑制敏感。
